Prostate cancer is the most common male cancer in Finland and Western countries is and it is the second leading cause of cancer deaths. The major clinical challenge for prostate cancer treatment is targeting the most aggressive disease spread to other parts of the body and that is resistant to therapies. Recent studies have shown that one fourth of patients treated with hormonal therapy develop a treatment-induced neuroendocrine disease that it is lethal with a survival rate of less than a year after diagnosis. This project is based on a discovery of cellular signaling pathway mechanisms in treatment-resistant prostate cancer patients. The aims of the project are to study the biology and mechanisms of the pathway members and also target their activity. This project has a great potential to result in a new approach for the diagnosis and/or therapy for lethal prostate cancer and to treat this incurable disease.

2023

2028